Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2016-05-30 Regulatory Filings
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
CPFR
Regulatory Filings Classification · 1% confidence The document is a press release from AB Science dated May 30, 2016, announcing that Phase 3 study data for masitinib in severe systemic mastocytosis will be presented orally at the 21st European Hematology Association (EHA) Congress in June 2016. It details the study objectives, population, and context of the presentation. This is not a full financial report (10-K or IR), an earnings release (ER), or a formal regulatory filing like a proxy statement. It is an announcement about upcoming scientific data presentation, which falls under general investor/corporate communication regarding research progress. Since it is a specific announcement about scientific data presentation at a conference, it is best classified as an Investor Presentation (IP) or a general Regulatory Filing (RNS). Given the focus on presenting study results, 'Investor Presentation' (IP) is a strong fit, as these announcements often precede or accompany the actual presentation materials. However, since the text itself is an announcement *about* a presentation, and not the presentation slides themselves, and it is a general corporate communication, 'Regulatory Filings' (RNS) serves as a broad category for such non-standard announcements, but 'Investor Presentation' (IP) captures the essence of communicating clinical data to investors better than RNS, even if it's just the announcement of the presentation.
2016-05-30 French
CPEng
Regulatory Filings Classification · 1% confidence The document is a press release dated May 30, 2016, announcing that AB Science will present Phase 3 trial data for masitinib in severe systemic mastocytosis at the 21st Congress of the European Hematology Association (EHA). It details the abstract, session title, and schedule for the presentation. This is not a full financial report (like 10-K or IR), nor is it a transcript (CT) or a formal regulatory filing like a proxy statement or earnings release. It is an announcement about scientific/clinical data presentation, which falls under general investor/corporate communication. Since there is no specific category for 'Clinical Data Presentation Announcement,' and it is a formal announcement detailing upcoming results presentation rather than the results themselves (which would likely be in an ER or IR), the most appropriate general category is Regulatory Filings (RNS) as a catch-all for significant, non-standard corporate announcements, or potentially Investor Presentation (IP) if it were the presentation slides themselves. Given the context of a press release announcing *where* data will be presented, RNS is the safest fallback, although it strongly resembles an Investor Presentation announcement. However, since it is announcing the presentation of data at a medical congress, and not a formal investor presentation document, RNS is chosen as the best fit among the provided options for a significant, non-financial regulatory/corporate update.
2016-05-30 English
DOCEng
AGM Information Classification · 1% confidence The document explicitly states that AB Science 'will hold its Annual General Meeting of Shareholders ("AGM") on June 28, 2016' and provides details regarding the meeting notice, agenda, resolutions, and instructions for participation and voting. This content directly relates to the preparation and announcement of the Annual General Meeting. Although it mentions the 2015 Annual Financial Report, the primary focus and purpose of this specific communication is the upcoming AGM. Therefore, the most appropriate classification is AGM Information (AGM-R). The document length (3847 chars) is substantial enough that it is not merely a placeholder announcement (RPA/RNS) but contains substantive details about the meeting logistics.
2016-05-25 English
DOCFR
AGM Information Classification · 1% confidence The document explicitly announces the date, time, and location for the 'Assemblée Générale des Actionnaires annuelle' (Annual General Meeting or AGM). It details the publication of the notice of meeting ('avis de réunion'), the availability of related documents, and instructions for voting and attendance. This content directly relates to the preparation and scheduling of the AGM. Therefore, the most appropriate classification is AGM Information (AGM-R). Although it mentions the 2015 Annual Report was published separately, the primary focus of this specific text is the upcoming meeting.
2016-05-25 French
CPEng
Regulatory Filings Classification · 1% confidence The document is an announcement dated May 2, 2016, stating that 'AB Science has submitted to EMA the marketing authorization application for Masitinib in the Treatment of Severe Systemic Mastocytosis'. This is a specific corporate action related to regulatory submission for a drug, not a general financial report (like 10-K, IR, or ER). It details the submission process, clinical trial results supporting the application, and future expectations regarding the EMA decision. This type of announcement, detailing progress in drug development and regulatory filings, fits best under the general category of corporate/regulatory news that doesn't align with the specific financial report codes. Given the options, it is a significant corporate announcement regarding regulatory progress. Since it is not a standard financial filing (10-K, IR, ER, etc.) and is a specific update on a regulatory process, it is best classified as a general Regulatory Filing (RNS) or potentially a Legal/Regulatory Update, but RNS serves as the best general regulatory announcement fallback when specific codes like LTR (Legal Proceedings) or CAP (Financing) do not apply. It is a direct announcement of a regulatory step taken.
2016-05-02 English
CPFR
Regulatory Filings Classification · 1% confidence The document is a press release from AB Science announcing the submission of a drug registration dossier (masitinib) to the European Medicines Agency (EMA). It details the clinical trial results, the nature of the drug, and the company's background. It does not fit into financial reporting categories like 10-K or IR, nor is it a simple report publication announcement. It is a general regulatory/corporate announcement regarding business operations and product development, which falls under the RNS (Regulatory Filings) category. FY 2016
2016-05-02 French

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.